PA1010 / Palo Alto Pharma - LARVOL DELTA

Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients (clinicaltrials.gov) - P1b | N=36 | Completed | Sponsor: Zhejiang Palo Alto Pharmaceuticals, Inc. | Recruiting ➔ Completed

Trial completion • Hepatitis B • Hepatology • Infectious Disease • Inflammation